BusinessAurobindo Pharma's Acrotech launches Adquey in US dermatology market
Aurobindo Pharma's subsidiary Acrotech Biopharma launched Adquey ointment in the US, entering the American dermatology market. Adquey is a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in adults and children aged two and above. Originally discovered by Otsuka Pharmaceutical, it is licensed to Acrotech for US commercialization. The company has created a dedicated dermatology unit to support this launch, targeting a market worth about USD 1.3 billion by July 2026.
Business Standard·4h ago




